Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cariprazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 11/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 11/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cariprazine SCHEMBL183804 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL30574605 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL29393456 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL30225016 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL183803 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL184342 | 0.99 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL29395059 | 0.99 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL26301652 | 0.99 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL184343 | 0.99 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| Cariprazine SCHEMBL1775021 | 0.98 | DRD2 (0.98) | DRD2DRD3HTR1ADRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943621-B2 | Salts of piperazine compounds as D3/D2 antagonists | RICHTER GEDEON NYRT. (HU) | 2011-05-17 | — | — | US | claimed |
| US-20090023750-A1 | NOVEL SALTS OF PIPERAZINE COMPOUNDS AS D3/D2 ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2009-01-22 | — | — | US | claimed |
| EP-2155696-B1 | PIPERAZINE SALTS AS D3/D2 ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2017-03-22 | — | — | EP | disclosed |
| US-7943621-B2 | Salts of piperazine compounds as D3/D2 antagonists | RICHTER GEDEON NYRT. (HU) | 2011-05-17 | — | — | US | disclosed |
| US-20090023750-A1 | NOVEL SALTS OF PIPERAZINE COMPOUNDS AS D3/D2 ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023750-A1 | NOVEL SALTS OF PIPERAZINE COMPOUNDS AS D3/D2 ANTAGONISTS | DRD2, DRD3, DRD4 | DRD2 1/4885DRD3 2/4885HTR1A 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.